Most popular ETFs | ||||||
iShares Core MSCI World UCITS ETF USD (Acc) | IE00B4L5Y983 | Equity | ETF | |||
Xtrackers MSCI Emerging Markets UCITS ETF 1C | IE00BTJRMP35 | Equity | ETF | |||
Vanguard FTSE All-World UCITS ETF Distributing | IE00B3RBWM25 | Equity | ETF | |||
iShares Global Clean Energy UCITS ETF USD (Dist) | IE00B1XNHC34 | Equity | ETF | |||
ETC Group Physical Bitcoin | DE000A27Z304 | Cryptocurrencies | ETN |
Most popular categories |
Equity, World |
Equity, Dividend strategy |
Bonds, Government, EUR |
The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.
Solactive Pharma Breakthrough Value (1)
Equity (1581) World (461) Health Care (23) Innovation (13)
Replication |
Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk |
Currency unhedged |
Volatility 1 year (in EUR) |
18.84%
![]() |
Inception/ Listing Date | 23 January 2018 |
Distribution policy | Accumulating | |
Distribution frequency | - | |
Fund domicile | Ireland | |
Tax data | Bundesanzeiger |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Fund Provider | Legal & General (LGIM) |
Administrator | BNY Mellon Fund Services (Ireland) Limited |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Select your savings amount:
Broker | Rating | Savings plan offer | Brokerage fee | More information |
---|---|---|---|---|
![]() |
free of charge
|
free of charge
|
More info | |
![]() |
free of charge
|
free of charge
|
More info | |
![]() |
free of charge
|
free of charge
|
More info | |
![]() |
EUR 1.50
1.50%
|
free of charge
|
More info | |
![]() |
EUR 1.50
1.50%
|
free of charge
|
More info |
Below you find information about the composition of the L&G Pharma Breakthrough UCITS ETF.
VERTEX PHARMACEUTICALS ORD |
3.47%
|
ASTRAZENECA PLC ADR |
3.44%
|
PTC THERAPEUTI/D |
3.44%
|
JCR PHARMACEUTICALS CO LTD |
3.40%
|
KYOWA HAKKO KIRIN CO LTD |
3.33%
|
SWEDISH ORPHAN BIOVITRUM ORD |
3.31%
|
GENMAB ORD |
3.31%
|
BIOGEN INC |
3.30%
|
NIPPON SHINYAKU ORD |
3.26%
|
HORIZON THERAPEUTICS PLC |
3.23%
|
Health Care |
99.83%
|